Solventum (SOLV) Up 11.4% Since Last Earnings Report: Can It Continue?
Solventum (SOLV) reported earnings 30 days ago. What's next for the stock?
Zacks Investment Research9/4/2026Positive
SOLV
Solventum Corp.NYSEHEALTHCAREMEDICAL INSTRUMENTS & SUPPLIES
Key Statistics
Market Cap
$15.61B
P/E Ratio
11.21
EPS
$8.18
Beta
0.69
52W High
$94.16
52W Low
$62.38
50-Day MA
$84.01
200-Day MA
$77.39
Dividend Yield
—
Profit Margin
17.30%
Forward P/E
13.68
PEG Ratio
1.22
About Solventum Corp.
Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. The company is headquartered in Saint Paul, Minnesota.
Fundamentals
| Revenue (TTM) | $8.31B |
| Gross Profit (TTM) | $4.55B |
| EBITDA | $1.14B |
| Operating Margin | 9.78% |
| Return on Equity | 34.00% |
| Return on Assets | 2.70% |
| Revenue/Share (TTM) | $47.79 |
| Book Value | $28.22 |
| Price-to-Book | 3.28 |
| Price-to-Sales (TTM) | 1.88 |
| EV/Revenue | 2.481 |
| EV/EBITDA | 8.36 |
| Quarterly Earnings Growth (YoY) | 3.90% |
| Quarterly Revenue Growth (YoY) | 2.20% |
| Shares Outstanding | $170.22M |
| Float | $144.09M |
| % Insiders | 15.34% |
| % Institutions | 75.97% |
Historical Volatility
HV 10-Day
12.58%
HV 20-Day
18.74%
HV 30-Day
33.69%
HV 60-Day
31.68%
HV Rank
78.6%
Volatility is currently contracting
Analyst Ratings
Consensus ($93.92 target)
1
Strong Buy7
Buy5
Hold1
Sell1
Strong SellLatest News
Solventum to Participate in the 2026 Wells Fargo Healthcare Conference
EAGAN, Minn., Sept. 2, 2026 /PRNewswire/ -- Solventum (NYSE: SOLV) announced today that management will participate in a fireside chat at the Wells Fargo Healthcare Conference on Wednesday, Sept.
PRNewsWire9/2/2026Neutral
Should Investors Buy SOLV as Growth Improves but Debt Risks Persist?
Solventum's growth, higher earnings outlook and cost cuts strengthen its case, but heavy debt and 2027 margin risks temper the upside.
Zacks Investment Research9/2/2026Positive
Why Solventum (SOLV) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks Investment Research8/17/2026Positive
SOLV Plans Health Information Systems Business Spinoff to Drive Growth
Solventum plans to spin off its $1.4B HIS business, sharpening its MedTech focus while giving HIS more flexibility to pursue growth.
Zacks Investment Research8/14/2026Positive
Here's Why Solventum (SOLV) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks Investment Research8/10/2026Positive
Solventum Stock Up as Q2 Earnings & Revenues Beat Estimates
SOLV's Q2 earnings and revenues beat estimates as organic sales increase 9.5%, prompting higher 2026 guidance despite ERP timing benefits.
Zacks Investment Research8/6/2026Positive
Solventum Reports Second Quarter 2026 Financial Results
Reported sales increased 2.2%; organic sales increased 9.5% Announces intent to separate its Health Information Systems business segment Increases full-year 2026 guidance for organic sales growth, adjusted EPS and free cash flow EAGAN, Minn., Aug. 5, 2026 /PRNewswire/ -- Solventum (NYSE: SOLV) today reported financial results for the second quarter ended June 30, 2026.
PRNewsWire8/5/2026Neutral
Solventum Announces Intent to Separate its Health Information Systems Business
Strengthens the focus of Solventum as a dedicated MedTech company and advances its three-phase transformation strategy Positions Health Information Systems, a leading, scaled, healthcare software business, to accelerate its strategic vision and growth agenda as a separate entity Unlocks shareholder value and enables targeted investment supporting innovation and growth across both businesses EAGAN, Minn., Aug. 5, 2026 /PRNewswire/ -- Solventum (NYSE: SOLV) today announced its intention to pursue a separation of its Health Information Systems business as part of the company's ongoing portfolio optimization strategy.
PRNewsWire8/5/2026Neutral
What's in Store for These 4 Healthcare Companies This Earnings Season?
McKesson, Cencora, Solventum and PacBio head into earnings with resilient demand offset by tariffs, funding pressure and pricing challenges.
Zacks Investment Research8/4/2026Negative
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on SOLV and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 9/7/2026